https://orcid.org/0000-0002-1610-0335
References
- Bui DS, Walters HE, Burgess JA, et al. Childhood respiratory risk factor profiles and middle-age lung function: a prospective cohort study from the first to sixth decade. Ann Am Thoracic Soc. 2018;15(9):1057–1066. doi:10.1513/annalsats.201806-374oc
- Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7. doi:10.3389/fped.2019.00246
- McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med. 2016;374(19):1842–1852. doi:10.1056/nejmoa1513737
- Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107(1):61–67. doi:10.1067/mai.2001.111590
- Fielding S, Pijnenburg M, de Jongste JC, et al. Change in FEV1 and FeNO measurements as predictors of future asthma outcomes in children. Chest. 2019;155(2):331–341. doi:10.1016/j.chest.2018.10.009
- Dunican EM, Fahy JV. The role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thoracic Soc. 2015;12(Supplement 2):S144–S149. doi:10.1513/annalsats.201506-377aw
- Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 MB of mouse immunoglobulin genes. Proc Natl Acad Sci. 2014;111(14):5147–5152. doi:10.1073/pnas.1323896111
- Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci. 2014;111(14):5153–5158. doi:10.1073/pnas.1324022111
- Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666x.2017.1298443
- Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385(24):2230–2240. doi:10.1056/nejmoa2106567
- Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23. doi:10.1034/j.1399-3003.1999.14a06.x
- Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–242. doi:10.1016/j.jaci.2004.11.014
- Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2021;60(1):2101499. doi:10.1183/13993003.01499-2021
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/nejmoa1804092
- Hanania NA, Maspero JF, Halpin DM, et al. Improvement in lung function with dupilumab does not predict its effects on reducing asthma exacerbation. J Asthma Allergy. 2022;15:851–854. doi:10.2147/jaa.s354013